BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of ...
AI isn’t failing because it’s immature. It’s failing because companies overestimate readiness, expect magic ROI, ignore data ...
Discover six reasons EPD could surge in 2026—organic growth, ethane export upside, and market shifts—plus key risks. Click ...
Stockhead on MSN
Entropy’s psilocybin therapy shows rapid and sustained reduction of binge eating in 100pc of patients
Clinical-stage biotech Entropy Neurodynamics has received positive Phase 2a results for its psilocybin-based therapy in ...
Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...
Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...
New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, ...
CK0804, a novel Treg therapy, gains FDA orphan drug status for myelofibrosis, promising new hope for patients with limited treatment options. CK0804, an investigational allogeneic regulatory T cell ...
BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...
InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in ...
Tech Xplore on MSN
AI data centers could stabilize the power grid
The rapid development and widespread use of artificial intelligence (AI) systems is posing new challenges for electricity ...
Australian private health insurers are warning that proposed changes to private hospital funding could lead to a reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback